Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SMART-101 by Smart Immune for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Data Insights
SMART-101 by Smart Immune for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...